Method of dewatering in a continuous high internal phase emulsion foam forming process

Information

  • Patent Grant
  • 9809693
  • Patent Number
    9,809,693
  • Date Filed
    Thursday, October 20, 2016
    8 years ago
  • Date Issued
    Tuesday, November 7, 2017
    7 years ago
Abstract
A method for continuous High Internal Phase Emulsion (HIPE) foam production. A HIPE is produced then extruded onto a belt. After polymerization, a portion of the saturated aqueous phase is removed using a vacuum box. A nip insert is inserted under the vacuum box to raise the vacuum box leading to improved uniformity of the HIPE in the cross direction along the belt.
Description
FIELD OF THE INVENTION

This application relates to producing High Internal Phase Emulsion (HIPE) foams using a continuous process.


BACKGROUND OF THE INVENTION

An emulsion is a dispersion of one liquid in another liquid and generally is in the form of a water-in-oil mixture having an aqueous or water phase dispersed within a substantially immiscible continuous oil phase. Water-in-oil (or oil in water) emulsions having a high ratio of dispersed phase to continuous phase are known in the art as High Internal Phase Emulsions, also referred to as “HIPE” or HIPEs. At relatively high dispersed aqueous phase to continuous oil phase ratios the continuous oil phase becomes essentially a thin film separating and coating the droplet-like structures of the internal, dispersed aqueous phase. In certain HIPEs continuous oil phase can have one or more polymerizable monomers. These monomers can be polymerized, forming a cellular structure, for example a foam, having a cell size distribution defined by the size distribution of the dispersed, aqueous phase droplets.


HIPE foams can be formed in a continuous process, wherein a HIPE is formed and then moved through the various stages used to produce a HIPE foam. A movable support member, such as a belt, will typically be used to move a HIPE from one stage to the next. Following the formation of the HIPE the next stage involves the polymerization of the monomers present in the oil phase to produce a HIPE foam. Initiator, which is used to start polymerization, is generally added during HIPE formation either to the separate aqueous and continuous oil phases or to the HIPE during the emulsion making process. In addition to the presence of initiator, heat can be used to accelerate the polymerization reaction, for example the individual aqueous and oil phases may be heated to accelerate the polymerization reaction.


After polymerization occurs, the resulting HIPE foam is saturated with aqueous phase that needs to be removed to obtain substantially dry HIPE foam. HIPE foams can be squeezed free of most of the aqueous phase by using compression, for example, by running the HIPE foam through one or more pairs of nip rollers. The nip rollers can be positioned such that they squeeze the aqueous phase out of the HIPE foam. Because there is a need to create HIPE foam with a level of uniformity, the saturated aqueous phase should be squeezed out while maintaining a uniform cross direction moisture and salt profile while increasing possible belt width.


Therefore there exists a need for a way to improve aqueous phase removal from a HIPE foam using a nip to create a uniform cross direction moisture and salt profile while increasing belt width.


SUMMARY OF THE INVENTION

A method for removing an aqueous phase from an open-celled foam is described. The method includes providing a belt comprising a cross directional width; providing an open-celled foam; providing a vacuum box, wherein the vacuum box comprises a nip insert, wherein the nip insert is located below the vacuum box and is in direct contact with the vacuum box; placing the open-celled foam on the belt; and passing the open-celled foam over the vacuum box to remove a saturated aqueous phase.


A method for removing an aqueous phase from an open-celled foam is described. The method includes forming an emulsion from an oil phase comprising a monomer, a cross-linking agent, an emulsifier, and an aqueous phase; providing an extrusion device; providing a belt comprising a cross directional width; providing a vacuum box, wherein the vacuum box comprises a nip insert, wherein the nip insert is located below the vacuum box and is in direct contact with the vacuum box; extruding the emulsion on the belt; polymerizing the monomer in the oil phase of the emulsion; and passing the polymerized emulsion over the vacuum box to remove a saturated aqueous phase.


A method for producing a High Internal Phase Emulsion foam is described. The method includes forming a High Internal Phase Emulsion from an oil phase comprising a monomer, a cross-linking agent, an emulsifier, and an aqueous phase; providing an extrusion device; providing a belt comprising a cross directional width and a material positioned on the belt and moving therewith; providing a vacuum box; extruding the High Internal Phase Emulsion on the belt; polymerizing the monomer in the oil phase of the High Internal Phase Emulsion; and passing the High Internal Phase Emulsion over the vacuum box to remove a saturated aqueous phase.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a schematic side view of an extrusion process.



FIG. 2 is a schematic side view of an embodiment of the present invention.



FIG. 3 is a cross section schematic view of an embodiment of the present invention taken along 3-3.





DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method for continuous High Internal Phase Emulsion (HIPE) foam production. A HIPE is produced and then extruded onto a belt. The belt moves in a horizontal direction to transport the HIPE from the extrusion point to the following stages of HIPE foam production. After extrusion on the belt, the HIPE is polymerized. Following polymerization, the resulting HIPE foam is saturated with aqueous phase that needs to be removed to obtain a substantially dry HIPE foam. Removal of the saturated aqueous phase or dewatering may occur using nip rollers, and vacuum. Nip shims or inserts are placed under the vacuum at fixed intervals along the cross direction of the belt.


A High Internal Phase Emulsion (HIPE) can have two phases. One phase is a continuous oil phase having monomers that are polymerized to form a HIPE foam and an emulsifier to help stabilize the HIPE. The oil phase may also include one or more photoinitiators. The monomer component may be present in an amount of from about 80% to about 99%, and in certain embodiments from about 85% to about 95% by weight of the oil phase. The emulsifier component, which is soluble in the oil phase and suitable for forming a stable water-in-oil emulsion may be present in the oil phase in an amount of from about 1% to about 20% by weight of the oil phase. The emulsion may be formed at an emulsification temperature of from about 20° C. to about 130° C. and in certain embodiments from about 50° C. to about 100° C.


In general, the monomers will include from about 20% to about 97% by weight of the oil phase at least one substantially water-insoluble monofunctional alkyl acrylate or alkyl methacrylate. For example, monomers of this type may include C4-C18 alkyl acrylates and C2-C18 methacrylates, such as ethylhexyl acrylate, butyl acrylate, hexyl acrylate, octyl acrylate, nonyl acrylate, decyl acrylate, isodecyl acrylate, tetradecyl acrylate, benzyl acrylate, nonyl phenyl acrylate, hexyl methacrylate, 2-ethylhexyl methacrylate, octyl methacrylate, nonyl methacrylate, decyl methacrylate, isodecyl methacrylate, dodecyl methacrylate, tetradecyl methacrylate, and octadecyl methacrylate.


The oil phase may also have from about 2% to about 40%, and in certain embodiments from about 10% to about 30%, by weight of the oil phase, a substantially water-insoluble, polyfunctional crosslinking alkyl acrylate or methacrylate. This crosslinking comonomer, or crosslinker, is added to confer strength and resilience to the resulting HIPE foam. Examples of crosslinking monomers of this type may have monomers containing two or more activated acrylate, methacrylate groups, or combinations thereof. Nonlimiting examples of this group include 1,6-hexanedioldiacrylate, 1,4-butanedioldimethacrylate, trimethylolpropane triacrylate, trimethylolpropane trimethacrylate, 1,12-dodecyldimethacrylate, 1,14-tetradecanedioldimethacrylate, ethylene glycol dimethacrylate, neopentyl glycol diacrylate (2,2-dimethylpropanediol diacrylate), hexanediol acrylate methacrylate, glucose pentaacrylate, sorbitan pentaacrylate, and the like. Other examples of crosslinkers contain a mixture of acrylate and methacrylate moieties, such as ethylene glycol acrylate-methacrylate and neopentyl glycol acrylate-methacrylate. The ratio of methacrylate:acrylate group in the mixed crosslinker may be varied from 50:50 to any other ratio as needed.


Any third substantially water-insoluble comonomer may be added to the oil phase in weight percentages of from about 0% to about 15% by weight of the oil phase, in certain embodiments from about 2% to about 8%, to modify properties of the HIPE foams. In certain embodiments, “toughening” monomers may be desired which impart toughness to the resulting HIPE foam. These include monomers such as styrene, vinyl chloride, vinylidene chloride, isoprene, and chloroprene. Without being bound by theory, it is believed that such monomers aid in stabilizing the HIPE during polymerization (also known as “curing”) to provide a more homogeneous and better formed HIPE foam which results in better toughness, tensile strength, abrasion resistance, and the like. Monomers may also be added to confer flame retardancy as disclosed in U.S. Pat. No. 6,160,028 (Dyer) issued Dec. 12, 2000. Monomers may be added to confer color, for example vinyl ferrocene, fluorescent properties, radiation resistance, opacity to radiation, for example lead tetraacrylate, to disperse charge, to reflect incident infrared light, to absorb radio waves, to form a wettable surface on the HIPE foam struts, or for any other desired property in a HIPE foam. In some cases, these additional monomers may slow the overall process of conversion of HIPE to HIPE foam, the tradeoff being necessary if the desired property is to be conferred. Thus, such monomers can be used to slow down the polymerization rate of a HIPE. Examples of monomers of this type can have styrene and vinyl chloride.


The oil phase may further contain an emulsifier used for stabilizing the HIPE. Emulsifiers used in a HIPE can include: (a) sorbitan monoesters of branched C16-C24 fatty acids; linear unsaturated C16-C22 fatty acids; and linear saturated C12-C14 fatty acids, such as sorbitan monooleate, sorbitan monomyristate, and sorbitan monoesters, sorbitan monolaurate diglycerol monooleate (DGMO), polyglycerol monoisostearate (PGMIS), and polyglycerol monomyristate (PGMM); (b) polyglycerol monoesters of -branched C16-C24 fatty acids, linear unsaturated C16-C22 fatty acids, or linear saturated C12-C14 fatty acids, such as diglycerol monooleate (for example diglycerol monoesters of C18:1 fatty acids), diglycerol monomyristate, diglycerol monoisostearate, and diglycerol monoesters; (c) diglycerol monoaliphatic ethers of -branched C16-C24 alcohols, linear unsaturated C16-C22 alcohols, and linear saturated C12-C14 alcohols, and mixtures of these emulsifiers. See U.S. Pat. No. 5,287,207 (Dyer et al.), issued Feb. 7, 1995 and U.S. Pat. No. 5,500,451 (Goldman et al.) issued Mar. 19, 1996. Another emulsifier that may be used is polyglycerol succinate (PGS), which is formed from an alkyl succinate, glycerol, and triglycerol.


Such emulsifiers, and combinations thereof, may be added to the oil phase so that they can have between about 1% and about 20%, in certain embodiments from about 2% to about 15%, and in certain other embodiments from about 3% to about 12% by weight of the oil phase. In certain embodiments, coemulsifiers may also be used to provide additional control of cell size, cell size distribution, and emulsion stability, particularly at higher temperatures, for example greater than about 65° C. Examples of coemulsifiers include phosphatidyl cholines and phosphatidyl choline-containing compositions, aliphatic betaines, long chain C12-C22 dialiphatic quaternary ammonium salts, short chain C1-C4 dialiphatic quaternary ammonium salts, long chain C12-C22 dialkoyl(alkenoyl)-2-hydroxyethyl, short chain C1-C4 dialiphatic quaternary ammonium salts, long chain C12-C22 dialiphatic imidazolinium quaternary ammonium salts, short chain C1-C4 dialiphatic imidazolinium quaternary ammonium salts, long chain C12-C22 monoaliphatic benzyl quaternary ammonium salts, long chain C12-C22 dialkoyl(alkenoyl)-2-aminoethyl, short chain C1-C4 monoaliphatic benzyl quaternary ammonium salts, short chain C1-C4 monohydroxyaliphatic quaternary ammonium salts. In certain embodiments, ditallow dimethyl ammonium methyl sulfate (DTDMAMS) may be used as a coemulsifier.


The oil phase may comprise a photoinitiator at between about 0.05% and about 10%, and in certain embodiments between about 0.2% and about 10% by weight of the oil phase. Lower amounts of photoinitiator allow light to better penetrate the HIPE foam, which can provide for polymerization deeper into the HIPE foam. However, if polymerization is done in an oxygen-containing environment, there should be enough photoinitiator to initiate the polymerization and overcome oxygen inhibition. Photoinitiators can respond rapidly and efficiently to a light source with the production of radicals, cations, and other species that are capable of initiating a polymerization reaction. The photoinitiators used in the present invention may absorb UV light at wavelengths of about 200 nanometers (nm) to about 800 nm, in certain embodiments about 200 nm to about 350 nm. If the photoinitiator is in the oil phase, suitable types of oil-soluble photoinitiators include benzyl ketals, a-hydroxyalkyl phenones, α-amino alkyl phenones, and acylphospine oxides. Examples of photoinitiators include 2,4,6-[trimethylbenzoyldiphosphine]oxide in combination with 2-hydroxy-2-methyl-1-phenylpropan-1-one (50:50 blend of the two is sold by Ciba Speciality Chemicals, Ludwigshafen, Germany as DAROCUR® 4265); benzyl dimethyl ketal (sold by Ciba Geigy as IRGACURE 651); α-,α-dimethoxy-α-hydroxy acetophenone (sold by Ciba Speciality Chemicals as DAROCUR® 1173); 2-methyl-1-[4-(methyl thio) phenyl]-2-morpholino-propan-1-one (sold by Ciba Speciality Chemicals as IRGACURE® 907); 1-hydroxycyclohexyl-phenyl ketone (sold by Ciba Speciality Chemicals as IRGACURE® 184); bis(2,4,6-trimethylbenzoyl)-phenylphosphineoxide (sold by Ciba Speciality Chemicals as IRGACURE 819); diethoxyacetophenone, and 4-(2-hydroxyethoxy)phenyl-(2-hydroxy-2-methylpropyl) ketone (sold by Ciba Speciality Chemicals as IRGACURE® 2959); and Oligo [2-hydroxy-2-methyl-1-[4-(1-methylvinyl) phenyl]propanone] (sold by Lambeth spa, Gallarate, Italy as ESACURE® KIP EM.


The dispersed aqueous phase of a HIPE can have water, and may also have one or more components, such as initiator, photoinitiator, or electrolyte, wherein in certain embodiments, the one or more components are at least partially water soluble.


One component of the aqueous phase may be a water-soluble electrolyte. The water phase may contain from about 0.2% to about 40%, in certain embodiments from about 2% to about 20%, by weight of the aqueous phase of a water-soluble electrolyte. The electrolyte minimizes the tendency of monomers, comonomers, and crosslinkers that are primarily oil soluble to also dissolve in the aqueous phase. Examples of electrolytes include chlorides or sulfates of alkaline earth metals such as calcium or magnesium and chlorides or sulfates of alkali earth metals such as sodium. Such electrolyte can include a buffering agent for the control of pH during the polymerization, including such inorganic counterions as phosphate, borate, and carbonate, and mixtures thereof. Water soluble monomers may also be used in the aqueous phase, examples being acrylic acid and vinyl acetate.


Another component that may be present in the aqueous phase is a water-soluble free-radical initiator. The initiator can be present at up to about 20 mole percent based on the total moles of polymerizable monomers present in the oil phase. In certain embodiments, the initiator is present in an amount of from about 0.001 to about 10 mole percent based on the total moles of polymerizable monomers in the oil phase. Suitable initiators include ammonium persulfate, sodium persulfate, potassium persulfate, 2,2′-azobis(N,N′-dimethyleneisobutyramidine)dihydrochloride, and other suitable azo initiators. In certain embodiments, to reduce the potential for premature polymerization which may clog the emulsification system, addition of the initiator to the monomer phase may be just after or near the end of emulsification.


Photoinitiators present in the aqueous phase may be at least partially water soluble and can have between about 0.05% and about 10%, and in certain embodiments between about 0.2% and about 10% by weight of the aqueous phase. Lower amounts of photoinitiator allow light to better penetrate the HIPE foam, which can provide for polymerization deeper into the HIPE foam. However, if polymerization is done in an oxygen-containing environment, there should be enough photoinitiator to initiate the polymerization and overcome oxygen inhibition. Photoinitiators can respond rapidly and efficiently to a light source with the production of radicals, cations, and other species that are capable of initiating a polymerization reaction. The photoinitiators used in the present invention may absorb UV light at wavelengths of from about 200 nanometers (nm) to about 800 nm, in certain embodiments from about 200 nm to about 350 nm, and in certain embodiments from about 350 nm to about 450 nm. If the photoinitiator is in the aqueous phase, suitable types of water-soluble photoinitiators include benzophenones, benzils, and thioxanthones. Examples of photoinitiators include 2,2′-Azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride; 2,2′-Azobis[2-(2-imidazolin-2-yl)propane]disulfate dehydrate; 2,2′-Azobis(1-imino-1-pyrrolidino-2-ethylpropane)dihydrochloride; 2,2′-Azobis[2-methyl-N-(2-hydroxyethyl)propionamide]; 2,2′-Azobis(2-methylpropionamidine)dihydrochloride; 2,2′-dicarboxymethoxydibenzalacetone, 4,4′-dicarboxymethoxydibenzalacetone, 4,4-dicarboxymethoxydibenzalcyclohexanone, 4-dimethylamino-4′-carboxymethoxydibenzalacetone; and 4,4′-disulphoxymethoxydibenzalacetone. Other suitable photoinitiators that can be used in the present invention are listed in U.S. Pat. No. 4,824,765 (Sperry et al.) issued Apr. 25, 1989.


In addition to the previously described components other components may be included in either the aqueous or oil phase of a HIPE. Examples include antioxidants, for example hindered phenolics, hindered amine light stabilizers; plasticizers, for example dioctyl phthalate, dinonyl sebacate; flame retardants, for example halogenated hydrocarbons, phosphates, borates, inorganic salts such as antimony trioxide or ammonium phosphate or magnesium hydroxide; dyes and pigments; fluorescers; filler particles, for example starch, titanium dioxide, carbon black, or calcium carbonate; fibers; chain transfer agents; odor absorbers, for example activated carbon particulates; dissolved polymers; dissolved oligomers; and the like.


HIPE foam is produced from the polymerization of the monomers having the continuous oil phase of a HIPE. In certain embodiments, HIPE foams may have one or more layers, and may be either homogeneous or heterogeneous polymeric open-celled foams. Homogeneity and heterogeneity relate to distinct layers within the same HIPE foam, which are similar in the case of homogeneous HIPE foams or which differ in the case of heterogeneous HIPE foams. A heterogeneous HIPE foam may contain at least two distinct layers that differ with regard to their chemical composition, physical properties, or both; for example layers may differ with regard to one or more of foam density, polymer composition, specific surface area, or pore size (also referred to as cell size). For example, for a HIPE foam if the difference relates to pore size, the average pore size in each layer may differ by at least about 20%, in certain embodiments by at least about 35%, and in still other embodiments by at least about 50%. In another example, if the differences in the layers of a HIPE foam relate to density, the densities of the layers may differ by at least about 20%, in certain embodiments by at least about 35%, and in still other embodiments by at least about 50%. For instance, if one layer of a HIPE foam has a density of 0.020 g/cc, another layer may have a density of at least about 0.024 g/cc or less than about 0.016 g/cc, in certain embodiments at least about 0.027 g/cc or less than about 0.013 g/cc, and in still other embodiments at least about 0.030 g/cc or less than about 0.010 g/cc. If the differences between the layers are related to the chemical composition of the HIPE or HIPE foam, the differences may reflect a relative amount difference in at least one monomer component, for example by at least about 20%, in certain embodiments by at least about 35%, and in still further embodiments by at least about 50%. For instance, if one layer of a HIPE or HIPE foam is composed of about 10% styrene in its formulation, another layer of the HIPE or HIPE foam should be composed of at least about 12%, and in certain embodiments of at least about 15%.


A HIPE foam having separate layers formed from differing HIPEs, as explained in more detail below, provides a HIPE foam with a range of desired performance characteristics. For example, a HIPE foam having a first and second foam layer, wherein the first foam layer has a relatively larger pore or cell size, than the second layer, when used in an absorbent article may more quickly absorb incoming fluids than the second layer. By way of example when used in an absorbent articled the first foam layer may be layered over the second foam layer having relatively smaller pore sizes, as compared to the first foam layer, which exert more capillary pressure and drain the acquired fluid from the first foam layer, restoring the first foam layer's ability to acquire more fluid. HIPE foam pore sizes may range in average diameter of from 1 to 200 μm and in certain embodiments may be less than 100 μm. HIPE foams produced from the present invention having two major parallel surfaces may be from 0.05 to 10 mm thick, and in certain embodiments 8 mm or less. The desired thickness of a HIPE will depend on the materials used to form the HIPE, the speed at which a HIPE is extruded on a belt, and the intended use of the resulting HIPE foam.


The HIPE foams produced from the present invention are relatively open-celled. This refers to the individual cells or pores of the HIPE foam being in substantially unobstructed communication with adjoining cells. The cells in such substantially open-celled HIPE foam structures have intercellular openings or windows that are large enough to permit ready fluid transfer from one cell to another within the HIPE foam structure. For purpose of the present invention, a HIPE foam is considered “open-celled” if at least about 80% of the cells in the HIPE foam that are at least 1 μm in average diameter size are in fluid communication with at least one adjoining cell.


In addition to being open-celled, in certain embodiments HIPE foams are sufficiently hydrophilic to permit the HIPE foam to absorb aqueous fluids, for example the internal surfaces of a HIPE foam may be rendered hydrophilic by residual hydrophilizing surfactants or salts left in the HIPE foam following polymerization, by selected post-polymerization HIPE foam treatment procedures (as described hereafter), or combinations of both.


In certain embodiments, for example when used in certain absorbent articles, a HIPE foam may be flexible and exhibit an appropriate glass transition temperature (Tg). The Tg represents the midpoint of the transition between the glassy and rubbery states of the polymer. In general, HIPE foams that have a higher Tg than the temperature of use can be very strong but will also be rigid and potentially prone to fracture. In certain embodiments, regions of the HIPE foams of the current invention which exhibit either a relatively high Tg or excessive brittleness will be discontinuous. Since these discontinuous regions will also generally exhibit high strength, they can be prepared at lower densities without compromising the overall strength of the HIPE foam.


HIPE foams intended for applications requiring flexibility should contain at least one continuous region having a Tg as low as possible, so long as the overall HIPE foam has acceptable strength at in-use temperatures. In certain embodiments, the Tg of this region will be less than about 30° C. for foams used at about ambient temperature conditions, in certain other embodiments less than about 20° C. For HIPE foams used in applications wherein the use temperature is higher or lower than ambient, the Tg of the continuous region may be no more that 10° C. greater than the use temperature, in certain embodiments the same as use temperature, and in further embodiments about 10° C. less than use temperature wherein flexibility is desired. Accordingly, monomers are selected as much as possible that provide corresponding polymers having lower Tg's.


The HIPE foams produced from the present invention may be used as absorbent core materials in absorbent articles, such as feminine hygiene articles, for example pads, pantiliners, and tampons; disposable diapers; incontinence articles, for example pads, adult diapers; homecare articles, for example wipes, pads, towels; and beauty care articles, for example pads, wipes, and skin care articles, such as used for pore cleaning.


To produce a HIPE using the above, an aqueous phase and an oil phase are combined in a ratio between about 8:1 and 140:1. In certain embodiments, the aqueous phase to oil phase ratio is between about 10:1 and about 75:1, and in certain other embodiments the aqueous phase to oil phase ratio is between about 13:1 and about 65:1. This is termed the “water-to-oil” or W:O ratio and can be used to determine the density of the resulting HIPE foam. As discussed, the oil phase may contain one or more of monomers, comonomers, photoinitiators, crosslinkers, and emulsifiers, as well as optional components. The water phase will contain water and in certain embodiments one or more components such as electrolyte, initiator, or optional components.


The HIPE can be formed from the combined aqueous and oil phases by subjecting these combined phases to shear agitation in a mixing chamber or mixing zone. The combined aqueous and oil phases are subjected to shear agitation to produce a stable HIPE having aqueous droplets of the desired size. An initiator may be present in the aqueous phase, or an initiator may be introduced during the HIPE making process, and in certain embodiments, after the HIPE has been formed but before the HIPE has been extruded on a belt. The emulsion making process produces a HIPE where the aqueous phase droplets are dispersed to such an extent that the resulting HIPE foam will have the desired structural characteristics. Emulsification of the aqueous and oil phase combination in the mixing zone may involve the use of a mixing or agitation device such as an impeller, by passing the combined aqueous and oil phases through a series of static mixers at a rate necessary to impart the requisite shear, or combinations of both. Once formed, the HIPE can then be withdrawn or pumped from the mixing zone. One method for forming HIPEs using a continuous process is described in U.S. Pat. No. 5,149,720 (DesMarais et al), issued Sep. 22, 1992; U.S. Pat. No. 5,827,909 (DesMarais) issued Oct. 27, 1998; and U.S. Pat. No. 6,369,121 (Catalfamo et al.) issued Apr. 9, 2002.


In certain embodiments, as shown in FIG. 1, for a continuous process a HIPE can be withdrawn or pumped from the mixing zone and extruded on to a carrier sheet 10 disposed on a belt, such as an endless belt 20 travelling in a substantially horizontal direction. The HIPE may also be extruded on to the belt 20 directly. The HIPE may be extruded through one or more extruding devices such as a die 30 (as shown in FIG. 1), sprayer, or caster. In certain embodiments, a HIPE is extruded in a substantially even thickness across the width of the carrier sheet 10 to form a sheet-like material. The average thickness of a HIPE, as measured from the surface of the HIPE that is in contact with the belt to the opposing HIPE surface, can be adjusted by the movement speed of the belt, the flow of HIPE extruded on the belt, or the configuration of one or more extruding devices used to extrude the HIPE on a belt.


Examples of belts may include endless belts made of one or more metals, a resin, or combinations thereof; or sheet materials such as films that may be positioned on the belt and moving therewith. The average thickness of the HIPE, as measured from the surface of the HIPE that is in contact with the belt to the opposing HIPE surface, can be adjusted by the movement speed of the belt, the flow of HIPE deposited on the belt, or the configuration of one or more depositing devices used to deposit the HIPE on a belt.


The belt can be any thickness or shape suitable for producing a HIPE foam. The belt has a cross directional width. Further, the surface of the belt upon which the HIPE will be deposited, can be substantially smooth or may contain depressions, protuberances, or combinations thereof. The protuberances or depressions may be arranged in any formation or order and can be used to provide patterns, designs, markings or the like to HIPE foam. The belt may contain one or more materials suitable for the polymerization conditions (various properties such as heat resistance, weatherability, surface energy, abrasion resistance, recycling property, tensile strength and other mechanical strengths) and may contain at least one material from the group including films, non-woven materials, woven materials, and combinations thereof. Examples of films include, fluorine resins such as polytetrafluoroethylene, tetrafluoroethylene-perfluoroalkylvinyl ether copolymers, tetrafluoroethylene-hexafluoropropylene copolymers, and tetrafluoroethylene-ethylene copolymers; silicone resins such as dimethyl polysiloxane and dimethylsiloxane-diphenyl siloxane copolymers; heat-resistant resins such as polyimides, polyphenylene sulfides, polysulfones, polyether sulfones, polyether imides, polyether ether ketones, and para type aramid resins; thermoplastic polyester resins such as polyethylene terephthalates, polybutylene terephthalates, polyethylene naphthalates, polybutylene naphthalates, and polycyclohexane terephthalates, thermoplastic polyester type elastomer resins such as block copolymers (polyether type) formed of PBT and polytetramethylene oxide glycol and block copolymers (polyester type) formed of PBT and polycaprolactone may be used. These materials may be used either singly or in mixed form of two or more materials. Further, the belt may be a laminate having two or more different materials or two or more materials of the same composition, but which differ in one or more physical characteristics, such as quality or thickness. In certain embodiments the belt or a film positioned on the belt and moving therewith may be transparent to UV light; allowing the UV light from a UV light source positioned below the belt, film or both to polymerize the monomers in a HIPE foam.


In one embodiment of the present invention, as shown in FIG. 1 the extruding device is a die 30 mounted on a die stand 31. The die 30 extrudes a HIPE on to a carrier sheet 10 which is supported by a support plate 11 and the underlying belt 20.


Further, maintenance of the die to carrier sheet surface gap, which is useful for uniform HIPE deposition, is much easier to maintain with the equipment of this invention, as the retractable piston assembly and drive assemblies are much lighter than either the die and associated mixing equipment or the belt pulley assembly, and can be positioned against a mechanical stop, for example as a way of reproducibly returning the carrier sheet to the proper position with respect to the die. A further advantage lies in the measurement of the above mentioned gap. If the heating zone is, for example a steam oven heated with steam, measuring the gap with gauges is not easily or safely done when the steam oven is at full temperature, but that is when the measurement should be made, as the steam oven will change dimensions significantly between the room temperature state and the target polymerization temperature. Also, attempting to control the gap by adjusting the position of the belt pulley interferes with the need to keep the belt tracked.


In certain embodiments, a carrier sheet moves the HIPE into a heating zone where the monomers present in the HIPE are polymerized. Without being bound by theory, it is believed that HIPE foam formation has two overlapping processes. These are the polymerization of the monomers and the formation of crosslinks between active sites on adjacent polymer backbones. As used herein the term “polymerize” as in to polymerize monomers to form a HIPE foam encompass both polymerization of monomers and formation of crosslinks between active sites on adjacent polymer backbones. Crosslinking provides HIPE foams with strength and integrity that is helpful to their further handling and use. The current invention involves increasing the overall level of polymerization and cross-linking, thereby reducing the amount of unpolymerized monomer in the HIPE foam. Polymerization can be initiated prior to reaching the heating zone by, for example, preparing the HIPE at a temperature sufficient to begin polymerization. However, the HIPE is polymerized beyond the point of shapability or moldability in the heating zone. Heat for the heating zone can be, for example, derived from an oven located above and below the HIPE or surrounding the HIPE. Heat can be from forced air ovens, IR heat lamps, microwave, steam or other suitable source. As an example of using steam the heat zone may be a steam oven wherein the HIPE is exposed to steam, thereby achieving highly efficient thermal transfer as water condenses onto the HIPE.


In certain embodiments, the temperature may be elevated in a step-wise manner so as to increase the rate of polymerization, initiate drying, or both as the HIPE becomes more completely polymerized. In addition, the curing of the HIPE may be accomplished by passing the web through a hot liquid bath composed of any hot liquid of sufficient temperature to initiate the curing of the monomers. Polymerization temperatures will vary depending on the type of emulsion being cured, the initiator being used, heat source used, and whether or not the heating zone is sealed, but will typically be above 25° C., often above 50° C. In certain embodiments, polymerization temperatures within the heating zone may reach between about 50° C. and 150° C. The HIPE is maintained in the heating zone for a time sufficient to polymerize at least 75%, preferably at least 90% of the monomers in the oil phase of the HIPE. Sufficient polymerization of the HIPE may be controlled by a combination of the initiator used, the temperature of the heat zone, the efficiency of the heat transfer in the heat zone, the rate at which the HIPE goes through the heat zone and the length of the heat zone.


The monomers present in the HIPE are substantially polymerized in the heating zone. In certain embodiments, in place of or in addition to a heating zone, Ultraviolet (UV) light may be used to polymerize the monomers of a HIPE. For example, a HIPE may be pre-polymerized using UV light before entering a curing oven, or a HIPE foam could be exposed to UV light upon exiting a curing oven to reduce the level of unreacted monomers, or the UV light could be used in place of a curing oven to polymerize the monomers of a HIPE. There may be one or more sources of UV light used to polymerize the HIPE monomers. The sources may be the same or differ. For example, the sources may differ in the wavelength of the UV light they produce or in the amount of time a HIPE is exposed to the UV light source. The UV light wavelength in the range from about 200 to about 400 nm, and in certain embodiments from about 200 nm to 350 nm, overlaps to at least some degree with the UV light absorption band of the photoinitiator and is of sufficient intensity and exposure duration to polymerize monomers in a HIPE.


Following polymerization, the resulting HIPE foam is saturated with aqueous phase that needs to be removed to obtain a substantially dry HIPE foam. In certain embodiments, HIPE foams can be squeezed free of most of the aqueous phase by using compression, for example by running the HIPE foam through one or more pairs of nip rollers. The nip rollers can be positioned such that they squeeze the aqueous phase out of the HIPE foam. The nip rollers can be porous and have a vacuum applied from the inside such that they assist in drawing aqueous phase out of the HIPE foam. In certain embodiments, nip rollers can be positioned in pairs, such that a first nip roller is located above a liquid permeable belt, such as a belt having pores or composed of a mesh-like material and a second opposing nip roller acing the first nip roller and located below the liquid permeable belt. One of the pair, for example the first nip roller can be pressurized while the other, for example the second nip roller, can be evacuated, so as to both blow and draw the aqueous phase out the of the HIPE foam. The nip rollers may also be heated to assist in removing the aqueous phase. In certain embodiments, nip rollers are only applied to non-rigid HIPE foams, that is HIPE foams whose walls would not be destroyed by compressing the HIPE foam. In yet a further embodiment, the surface of the nip rollers may contain irregularities in the form of protuberances, depressions, or both such that a HIPE foam can be embossed as it is moving through the nip rollers. When the HIPE has the desired dryness it may be cut or sliced into a form suitable for the intended application.


In certain embodiments, in place of or in combination with nip rollers, the aqueous phase may be removed by sending the HIPE foam through a drying zone where it is heated, exposed to a vacuum, or a combination of heat and vacuum exposure. Heat can be applied, for example, by running the foam though a forced air oven, IR oven, microwave oven or radiowave oven. The extent to which a HIPE foam is dried depends on the application. In certain embodiments, greater than 50% of the aqueous phase is removed. In certain other embodiments greater than 90%, and in still other embodiments greater than 95% of the aqueous phase is removed during the drying process.


In certain embodiments, as shown in FIG. 2 and FIG. 3, one or more nip inserts 50 may be located under the vacuum box 52. A nip insert 50 may be one or more layers of tape, a bolt, a washer, a screw, a piece of wood, and/or any other known item capable of propping an isolated point. The nip inserts 50 may be placed at intervals along the cross direction of the belt at a distance of about 0.5 inches to 5 inches. The nip inserts 50 may be placed at intervals along the cross direction of the belt at a distance of about 0.5 inch, 1 inch, 1.5 inches, 2 inches, 2.5 inches, 3 inches, 3.5 inches, 4 inches, and/or 5 inches apart. The nip insert 50 may raise the vacuum in contact with the belt by about 0.01 inch to 0.25 inch. The nip inserts 50 may be adjustable to raise the vacuum box 52 in contact with the belt between about 0.01 inch to about 0.25 inch. The nip insert 50 may raise the vacuum box 52 in contact with the belt by about 0.01 inch, 0.02 inch, 0.03 inch, 0.04 inch, 0.05 inch, 0.06 inch, 0.07 inch, 0.08 inch, 0.09 inch, 0.1 inch, 0.15 inch, 0.2 inch, or 0.25 inch at the point directly above the nip insert 50.


Without being bound to any theory, it is believed that raising the vacuum box leads to improved removal of the saturated aqueous phase at the specific points along the cross direction of the belt where the vacuum box is raised. To create a uniform moisture and salt profile, it is believed that placing nip inserts at set interval distances along the cross direction of the belt leads to an increased efficiency in the removal of the saturated aqueous phase while creating a more uniform final moisture and salt profile after vacuum. This can best be appreciated while increasing the length of the belt in the cross direction leading to a need for larger or multiple vacuum systems while still maintaining a need to create a HIPE that exhibits a uniform moisture and salt profile.


The effect of the nip inserts can be seen when comparing the 4 mL gush acquisition and caliper data of the final material with and without nip inserts as shown in Table 1. A belt is divided into lanes along the cross direction of the belt. Nip inserts are placed under individual lanes along the belt cross direction to determine the localized effect on moisture profiles. Using the nip inserts, one sees a decrease in Gush acquisition time for 4 mL of test fluid and an increase in dry caliper measurement.












TABLE 1









Gush Absorption (sec)
Dry Caliper mm












Without
With
Without
With



a Nip
a Nip
a Nip
a Nip


Lane/Height of Nip Insert
Insert
Insert
Insert
Insert














Test 1: Lane 3 at 0.05 inch
85.8
70.6
2.23
2.51


Test 2: Lane 6 at 0.04 inch
81.5
64.4
2.16
2.36


Test 3: Lane 3 at 0.05 inch
86.1
71.4
1.98
2.21


Test 3: Lane 4 at 0.05 inch
86.0
75.6
1.99
2.07









One of ordinary skill in the art would appreciate that the use of nip inserts to improve dewatering thereby creating a uniform moisture profile may be used in any dewatering process beyond HIPEs. Other dewatering processes may include regular foams, paper production, or any pulp based process utilizing belts and a vacuum to draw the aqueous phase from a composition.


Test Method Section:




  • HIPE 4 mL Gush Acquisition Time Test


    Purpose



This Test Method was developed to measure the time required for a known volume of fluid to pass through the upper layer and into the lower “storage” layer of Composite HIPE. The test fluid used in this test has viscous characteristics similar to menstrual fluid.


The test is run on raw material samples under the following conditions:

  • Fluid load: 4 mL
  • Confining pressure: 1.72 kPa (0.25 psi)


    Equipment
  • Pipette, capable of delivering 4.0+/−0.05 mL of fluid solution, from a convenient source.
  • Urethane foam pad, 0.04 g/cm2 at 1.25 cm thickness, from a convenient source.
  • Filter paper, grade no. 54, from a convenient source.
  • Buchner funnel and vacuum flask, from a convenient source.
  • Stopwatch, NIST traceable, with resolution the nearest 0.01 sec., from a convenient source.
  • Viscometer/rheometer, capable of measuring viscosity in the 5-10 cP range with a resolution to the nearest 0.01 cP.
  • Gush plate, 10.2 cm×10.2 cm.
  • Confining weight plates, 10.2×10.2 cm with 2.54 cm diameter hole in center (to deliver 1.72 kPa confining pressure when combined with Gush plate).
  • Top-loading analytical balance, with resolution to the nearest 0.01 g, from a convenient source.


    Test Procedure
  • 1. Place the HIPE Composite specimen large cell-side up on top of the foam pad.
  • 2. Place the Gush Plate on top of the HIPE specimen so the edges of the Gush Plate are aligned with the edges of the foam pad.
  • 3. Place the Weight Plate on top of the Gush Plate so the edges of the Weight Plate are aligned with the edges of the Gush Plate and foam pad. NOTE: The combined weight of the Gush Plate and Weight Plate shall be 1815+/−1 g to deliver the 1.72 kPa confining pressure.
  • 4. Using the pipette, deliver 4.0 mL of test fluid solution to the inner wall of the Gush plate, immediately above the portion of the HIPE large cell surface visible through the holes in the center of the Weight and Gush plates.
  • 5. Immediately start the timer.
  • 6. Observe the progress of the acquisition of CMC fluid into the HIPE specimen, and stop the timer when the last bit of test fluid disappears below the surface of the HIPE.
  • 7. Rinse any residual test fluid solution from the Gush Plate with water and thoroughly dry the plate before testing any additional specimens.


    Reporting


    Report the time in seconds (to the nearest 0.1 sec) for the test fluid to be acquired by the HIPE.


The dimensions and values disclosed herein are not to be understood as being strictly limited to the exact numerical values recited. Instead, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as “40 mm” is intended to mean “about 40 mm.”


Every document cited herein, including any cross referenced or related patent or application, is hereby incorporated herein by reference in its entirety unless expressly excluded or otherwise limited. The citation of any document is not an admission that it is prior art with respect to any invention disclosed or claimed herein or that it alone, or in any combination with any other reference or references, teaches, suggests or discloses any such invention. Further, to the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall govern.


While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.

Claims
  • 1. A method for removing an aqueous phase from an open-celled foam, the method comprising: providing a belt comprising a cross directional width;providing an open-celled foam;providing a vacuum box, wherein the vacuum box comprises a nip insert, wherein the nip insert is located below the vacuum box and is in direct contact with the vacuum box;placing the open-celled foam on the belt; andpassing the open-celled foam over the vacuum box to remove a saturated aqueous phase.
  • 2. The method of claim 1, wherein the vacuum box comprises a plurality of nip inserts, wherein each of the plurality of nip inserts impacts an individual vacuum box.
  • 3. The method of claim 1 wherein the nip insert is selected from the group consisting of one or more layers of tape, a bolt, a washer, a screw, a piece of wood, and/or combinations thereof.
  • 4. The method of claim 2, wherein the nip inserts are located at intervals along the belt cross directional width, wherein the intervals between nip inserts are between about 0.5 inch to about 5 inches.
  • 5. The method of claim 2, wherein the nip inserts are located at intervals along the belt cross directional width, wherein the intervals between nip inserts are between about 1 inch to about 3 inches.
  • 6. The method of claim 2, wherein the nip inserts raise the vacuum box by about 0.01 inch to about 0.1 inch.
  • 7. The method of claim 2, wherein the nip inserts raise the vacuum box by about 0.02 inch to about 0.05 inch.
  • 8. A method for removing an aqueous phase from an open-celled foam, the method comprising: forming an emulsion from an oil phase comprising a monomer, a cross-linking agent, an emulsifier, and an aqueous phase;providing an extrusion device;providing a belt comprising a cross directional width;providing a vacuum box, wherein the vacuum box comprises a nip insert, wherein the nip insert is located below the vacuum box and is in direct contact with the vacuum box;extruding the emulsion on the belt;polymerizing the monomer in the oil phase of the emulsion; andpassing the polymerized emulsion over the vacuum box to remove a saturated aqueous phase.
  • 9. The method of claim 8, wherein the vacuum box comprises a plurality of nip inserts, wherein each of the plurality of nip inserts impacts an individual vacuum box.
  • 10. The method of claim 8, wherein the nip insert is selected from the group consisting of one or more layers of tape, a bolt, a washer, a screw, a piece of wood, and/or combinations thereof.
  • 11. The method of claim 9, wherein the nip inserts are located at intervals along the belt cross directional width, wherein the intervals between nip inserts are between about 0.5 inch to about 5 inches.
  • 12. The method of claim 9, wherein the nip inserts are located at intervals along the belt cross directional width, wherein the intervals between nip inserts are between about 1 inch to about 3 inches.
  • 13. The method of claim 9, wherein the nip inserts raise the vacuum box by about 0.01 inch to about 0.1 inch.
  • 14. The method of claim 9, wherein the nip inserts raise the vacuum box by about 0.02 inch to about 0.05 inch.
  • 15. A method for producing a High Internal Phase Emulsion foam, the method comprising: forming a High Internal Phase Emulsion from an oil phase comprising a monomer, a cross-linking agent, an emulsifier, and an aqueous phase;providing an extrusion device;providing a belt comprising a cross directional width and a material positioned on the belt and moving therewith;providing a vacuum box;extruding the High Internal Phase Emulsion on the belt;polymerizing the monomer in the oil phase of the High Internal Phase Emulsion; andpassing the High Internal Phase Emulsion over the vacuum box to remove a saturated aqueous phase.
  • 16. The method of claim 15, wherein the vacuum box comprises a nip insert, wherein the nip insert is located below the vacuum box and is in direct contact with the vacuum box.
  • 17. The method of claim 15, wherein the vacuum box comprises a plurality of nip inserts, wherein each of the plurality of nip inserts impacts an individual vacuum box.
  • 18. The method of claim 16, wherein the nip insert is selected from the group consisting of one or more layers of tape, a bolt, a washer, a screw, a piece of wood, and/or combinations thereof.
  • 19. The method of claim 17, wherein the nip inserts are located at intervals along the belt cross directional width, wherein the intervals between nip inserts are between about 0.5 inch to about 5 inches.
  • 20. The method of claim 17, wherein the nip inserts raise the vacuum box by about 0.01 inch to about 0.1 inch.
US Referenced Citations (667)
Number Name Date Kind
2191857 Miller Feb 1940 A
2881675 James Apr 1959 A
2893136 Daane et al. Jul 1959 A
2951007 Lippke Aug 1960 A
3040807 Chope Jun 1962 A
3089252 Daane et al. May 1963 A
3161482 Gschwind et al. Dec 1964 A
3163503 Conture et al. Dec 1964 A
3167408 Justus et al. Jan 1965 A
3176411 Jepson et al. Apr 1965 A
3203850 McCarty Aug 1965 A
3214845 Huliman Nov 1965 A
3244206 Bossen Apr 1966 A
3260642 Canter Jul 1966 A
3284920 Jokihaara Nov 1966 A
3320677 Reitzel May 1967 A
3337968 Krikorian Aug 1967 A
3358378 Downs Dec 1967 A
3388479 Gardner Jun 1968 A
3399460 Russell Sep 1968 A
3406464 Clark Oct 1968 A
3409220 Black Nov 1968 A
3411075 Kahoun Nov 1968 A
3432656 Smith Mar 1969 A
3432936 Cole Mar 1969 A
3497802 Biddle Feb 1970 A
3519024 Johnson et al. Jul 1970 A
3533909 Bennett Oct 1970 A
3534381 McKeegan Oct 1970 A
3536258 Rocheleau Oct 1970 A
3547775 Bossen Dec 1970 A
3555700 Wagner Jan 1971 A
3559298 Theilemann Feb 1971 A
3564724 Keyes et al. Feb 1971 A
3590991 Sloan Jul 1971 A
3619359 Keyes Nov 1971 A
3622448 Adams et al. Nov 1971 A
3625812 Gudaz et al. Dec 1971 A
3658642 Keyes et al. Apr 1972 A
3662170 Keyes May 1972 A
3666621 Adams May 1972 A
3668401 Shah et al. Jun 1972 A
3668787 Berg et al. Jun 1972 A
3713966 Lippke Jan 1973 A
3726757 Dupasquier Apr 1973 A
3731520 Hickman et al. May 1973 A
3751373 Graffeo et al. Aug 1973 A
3762211 Poulsen Oct 1973 A
3774225 Kimmel et al. Nov 1973 A
3776471 Meyer et al. Dec 1973 A
3778908 Notbohm Dec 1973 A
3782192 Sandblom Jan 1974 A
3791049 Smith Feb 1974 A
3793741 Smith Feb 1974 A
3805401 Fontein Apr 1974 A
3829764 Bosisio Aug 1974 A
3837088 Lenz Sep 1974 A
3847730 Doering Nov 1974 A
3849904 Villalobos Nov 1974 A
3857023 McCall Dec 1974 A
3867766 Wagner Feb 1975 A
3872603 Schuette et al. Mar 1975 A
3872919 Maag Mar 1975 A
3878620 Gallahue Apr 1975 A
3879607 Bjorklund Apr 1975 A
3897638 Lenz Aug 1975 A
3925906 Chance et al. Dec 1975 A
3962799 Lapointe et al. Jun 1976 A
3967197 Anderson Jun 1976 A
3989085 Crosby Nov 1976 A
4077766 von der Eltz Mar 1978 A
4082504 von der Eltz Apr 1978 A
4086691 Smith May 1978 A
4091824 Psaras May 1978 A
4096643 Futcher Jun 1978 A
4109432 Pilz Aug 1978 A
4124942 Ohls et al. Nov 1978 A
4125945 Westelaken Nov 1978 A
4134731 Houser Jan 1979 A
4146972 Smith Apr 1979 A
4152202 DeLigt May 1979 A
4156843 Strandberg May 1979 A
4174863 Gotz Nov 1979 A
4188731 Rauskolb Feb 1980 A
4192080 Irpola Mar 1980 A
4193027 Wyslouzil Mar 1980 A
4194298 Hart Mar 1980 A
4204337 Roos May 1980 A
4205632 Tratz Jun 1980 A
4207143 Glomb Jun 1980 A
4247990 Ohls Feb 1981 A
4249992 Wells Feb 1981 A
4252443 Lucas Feb 1981 A
4253247 Bergstrom Mar 1981 A
4259431 Opitz Mar 1981 A
4266878 Auer May 1981 A
4267046 Stoev May 1981 A
4312139 Bilek et al. Jan 1982 A
4314878 Lee Feb 1982 A
4319185 Hill Mar 1982 A
4320583 Dove Mar 1982 A
4331510 Wells May 1982 A
4350757 Montag Sep 1982 A
4351700 Dove Sep 1982 A
4377985 Reba Mar 1983 A
4378207 Smith Mar 1983 A
4384514 Larive May 1983 A
4399403 Strandberg Aug 1983 A
4404951 Zechlin Sep 1983 A
4419889 Muto Dec 1983 A
4422575 Dove Dec 1983 A
4445788 Twersky May 1984 A
4474643 Linblad Oct 1984 A
4492044 Knutsen Jan 1985 A
4494316 Stephansen Jan 1985 A
4494319 Rudt Jan 1985 A
4498864 Roth Feb 1985 A
4500607 Louden Feb 1985 A
4514913 Stephansen May 1985 A
4517055 Dove May 1985 A
4526654 Johansson Jul 1985 A
4536970 Eskelinen Aug 1985 A
4539073 Andersson Sep 1985 A
4543737 Boissevain Oct 1985 A
4545857 Wells Oct 1985 A
4552570 Gravatt Nov 1985 A
4569069 LaMarche Feb 1986 A
4573402 Sharma Mar 1986 A
4580355 Boissevain Apr 1986 A
4583302 Smith Apr 1986 A
4586983 Laapotti et al. May 1986 A
4590685 Roth May 1986 A
4604054 Smith Aug 1986 A
4610530 Lehmbeck Sep 1986 A
4627176 Brieu Dec 1986 A
4628655 Scheiderer Dec 1986 A
4630535 Haygreen Dec 1986 A
4639291 Ota Jan 1987 A
4639292 Ota Jan 1987 A
4649964 Smith Mar 1987 A
4656333 Murphy Apr 1987 A
4662398 Wywailowski May 1987 A
4689895 Taylor Sep 1987 A
4694587 Eskelinen Sep 1987 A
4719728 Eriksson Jan 1988 A
4722681 Smith Feb 1988 A
4733078 Sturm Mar 1988 A
4757585 Niskanen et al. Jul 1988 A
4763424 Taylor Aug 1988 A
4767981 Pakulis Aug 1988 A
4791863 Vahatalo Dec 1988 A
4793250 Niskanen et al. Dec 1988 A
4823477 Soininen Apr 1989 A
4830651 Smith May 1989 A
4832711 Christel, Jr. May 1989 A
4836894 Chance Jun 1989 A
4838996 Kallmes Jun 1989 A
4845978 Whitford Jul 1989 A
4854052 Korpela et al. Aug 1989 A
4856154 Kainu et al. Aug 1989 A
4859926 Wolze Aug 1989 A
4873407 Smith Oct 1989 A
4874467 Karlsson Oct 1989 A
4878781 Gregory et al. Nov 1989 A
4882852 Kautto et al. Nov 1989 A
4888882 Ryham Dec 1989 A
4898476 Funken et al. Feb 1990 A
4899463 Heikkila Feb 1990 A
4908956 Grund Mar 1990 A
4918375 Malicki Apr 1990 A
4928013 Anderson et al. May 1990 A
4942675 Sundgvist Jul 1990 A
4942808 Benson Jul 1990 A
4944385 Shelby Jul 1990 A
4977687 Boissevain Dec 1990 A
4980846 Chapman Dec 1990 A
4987280 Kanafani Jan 1991 A
4988408 Evalahti Jan 1991 A
4990751 Nous Feb 1991 A
5009016 Ilmanen Apr 1991 A
5010659 Treleven Apr 1991 A
5011573 Niemi Apr 1991 A
5049216 Anderson Sep 1991 A
5062066 Scher Oct 1991 A
5065673 Taylor Nov 1991 A
5077913 Akerblom Jan 1992 A
5090133 Taylor Feb 1992 A
5092407 Laurenson Mar 1992 A
5093795 Lewis Mar 1992 A
5101578 Swanson Apr 1992 A
5106655 Boissevain Apr 1992 A
5108526 Cornils Apr 1992 A
5115582 Westhead May 1992 A
5116414 Burton May 1992 A
5124552 Anderson Jun 1992 A
5133185 Gilbreath Jul 1992 A
5137740 Benson Aug 1992 A
5145056 Smith Sep 1992 A
5159893 Rantanen Nov 1992 A
5163454 Clemons Nov 1992 A
5167979 Benson Dec 1992 A
5170357 Negishi Dec 1992 A
5197201 Salin Mar 1993 A
5235192 Chase Aug 1993 A
5240564 Niskanen Aug 1993 A
5260666 Dishman Nov 1993 A
5262955 Lewis Nov 1993 A
5286348 Perin Feb 1994 A
5304391 Rantanen Apr 1994 A
5338361 Anderson Aug 1994 A
5342486 Jeffery Aug 1994 A
5355595 Koivukunnas Oct 1994 A
5355649 Berridge Oct 1994 A
5372826 Holz Dec 1994 A
5377428 Clark Jan 1995 A
5385644 Hannus Jan 1995 A
5387782 Holik Feb 1995 A
5400258 He Mar 1995 A
5416979 Joiner May 1995 A
5416980 Ilvespaa May 1995 A
5419969 Miyazaki May 1995 A
5437107 Ensign Aug 1995 A
5437850 Kroehl Aug 1995 A
5465504 Joiner Nov 1995 A
5466176 Cornell Nov 1995 A
5495678 Ilmarinen Mar 1996 A
5512308 Hsieh Apr 1996 A
5524532 Koivukunnas Jun 1996 A
5528838 Timm Jun 1996 A
5540000 Rosenburgh Jul 1996 A
5548942 Zajec Aug 1996 A
5560350 Kim Oct 1996 A
5570521 Baker Nov 1996 A
5571944 Pfeifer Nov 1996 A
5584128 Ensign Dec 1996 A
5601236 Wold Feb 1997 A
5603806 Kerttula Feb 1997 A
5607553 Chadha Mar 1997 A
5616158 Biendarra Apr 1997 A
5616827 Simmermon Apr 1997 A
5621669 Bjornsson Apr 1997 A
5626667 Bohle May 1997 A
5630285 Kerttula May 1997 A
5632830 Marschke May 1997 A
5636126 Heaven Jun 1997 A
5649372 Souza Jul 1997 A
5649448 Koskimies Jul 1997 A
5649478 Chadha Jul 1997 A
5653041 Ilmarinen Aug 1997 A
5654799 Chase Aug 1997 A
5667641 Poirier Sep 1997 A
5674363 Huovila Oct 1997 A
5680987 Taylor Oct 1997 A
5695442 Leung Dec 1997 A
5696666 Miles Dec 1997 A
5697385 Seymour Dec 1997 A
5711087 Pazdera Jan 1998 A
5747904 Sudhoff May 1998 A
5756156 Elijoki May 1998 A
5759680 Brooks Jun 1998 A
5763559 Black Jun 1998 A
5775001 Kerttula Jul 1998 A
5795641 Pauley Aug 1998 A
5821498 Niskanen Oct 1998 A
5825653 Huovila Oct 1998 A
5837974 Sissons Nov 1998 A
5842853 Bohle Dec 1998 A
5862608 Kotitschke Jan 1999 A
5862613 Kerttula Jan 1999 A
5884225 Allen Mar 1999 A
5890372 Belding Apr 1999 A
5893055 Chen Apr 1999 A
5912072 Trokhan Jun 1999 A
5915813 Joiner Jun 1999 A
5928475 Chase Jul 1999 A
5933977 Deshpande Aug 1999 A
5933980 Deshpande Aug 1999 A
5937258 Acquaviva Aug 1999 A
5937538 Joiner Aug 1999 A
5938895 Hirvonen Aug 1999 A
5942130 Leung Aug 1999 A
5942322 Ensign Aug 1999 A
5950325 Freeman Sep 1999 A
5964956 Straub Oct 1999 A
5965075 Pauley Oct 1999 A
5977780 Herrmann Nov 1999 A
5980962 Bracken Nov 1999 A
5985893 Yu Nov 1999 A
5994045 Bourdelais Nov 1999 A
6003327 Belding Dec 1999 A
6018909 Potts Feb 2000 A
6020704 Buschur Feb 2000 A
6021583 Stelljes, Jr. Feb 2000 A
6030447 Duselis Feb 2000 A
6035710 Hutchison Mar 2000 A
6038789 Kaihovirta Mar 2000 A
6040669 Hog Mar 2000 A
6040805 Cheng Mar 2000 A
6045730 Potter Apr 2000 A
6053040 Callender Apr 2000 A
6053093 Gerhardt Apr 2000 A
6059931 Hu May 2000 A
6083346 Chen Jul 2000 A
6092375 Denniston Jul 2000 A
6094604 Bucher Jul 2000 A
6094838 Lang Aug 2000 A
6096169 Hermans Aug 2000 A
6098309 Halmschlager Aug 2000 A
6099690 Hu et al. Aug 2000 A
6105276 Ensign Aug 2000 A
6105498 Vrotacoe Aug 2000 A
6106671 Heaven et al. Aug 2000 A
6110096 Leung Aug 2000 A
6115397 Heritier Sep 2000 A
RE36921 Bushman et al. Oct 2000 E
6126787 Elijoki Oct 2000 A
6128833 Edelmann Oct 2000 A
6138380 Veijola Oct 2000 A
6143092 Straub Nov 2000 A
6149767 Hermans Nov 2000 A
6162331 Ruf Dec 2000 A
6169848 Henry Jan 2001 B1
6176976 Carter Jan 2001 B1
6179964 Begemann Jan 2001 B1
6187137 Druecke Feb 2001 B1
6187139 Edwards Feb 2001 B1
6193840 Elijoki Feb 2001 B1
6200422 Shakespeare Mar 2001 B1
6200425 Pellinen Mar 2001 B1
6210616 Suwanda Apr 2001 B1
6228220 Hada May 2001 B1
6245995 Coorod Jun 2001 B1
6251465 Bello Jun 2001 B1
6257133 Anderson Jul 2001 B1
6264792 Kuosa Jul 2001 B1
6273638 Clarkson Aug 2001 B1
6274001 Mohan Aug 2001 B1
6280576 Kuhasalo Aug 2001 B1
6287424 Mohan Sep 2001 B1
6299808 Mork Oct 2001 B1
6306257 Hada Oct 2001 B1
6318727 Hada Nov 2001 B1
6322666 Luotama Nov 2001 B1
6332953 Singh Dec 2001 B1
6334579 Zarbi Jan 2002 B1
6339727 Ladd Jan 2002 B1
6340412 Niemi Jan 2002 B1
6354531 Aalto Mar 2002 B1
6365004 Hamstr Apr 2002 B1
6379496 Edwards et al. Apr 2002 B2
6383338 Meschenmoser May 2002 B1
6387218 Graf May 2002 B1
6393729 Forsman May 2002 B1
6394418 Duan May 2002 B1
6401355 Linnonmaa Jun 2002 B1
6412189 Pellinen Jul 2002 B1
6432267 Watson Aug 2002 B1
6436234 Chen Aug 2002 B1
6442492 Jackson Aug 2002 B1
6447583 Thelen Sep 2002 B1
6449874 Pellinen Sep 2002 B2
6460775 Duan Oct 2002 B1
6463677 Wolf Oct 2002 B2
6463794 Moshe Oct 2002 B1
6475259 Thomas Nov 2002 B1
6485610 Loippo Nov 2002 B1
6490813 Oechsle Dec 2002 B1
6491791 Loippo Dec 2002 B1
6497790 Mohan et al. Dec 2002 B2
6523278 Coulson Feb 2003 B1
6523401 Oechsle Feb 2003 B2
6526369 Meinecke Feb 2003 B1
6527363 Bowling Mar 2003 B1
6533889 Dueholm Mar 2003 B2
6544156 Anderson Apr 2003 B2
6549852 Hanson Apr 2003 B2
6551454 Ewens Apr 2003 B1
6560893 Bakalar May 2003 B1
6569288 Linnonmaa May 2003 B1
6579418 Lindsay Jun 2003 B2
6582648 Reif Jun 2003 B1
6584703 Menpaa et al. Jul 2003 B1
6589388 Nissinen Jul 2003 B1
6596316 Lyons et al. Jul 2003 B2
6602341 Hogg Aug 2003 B1
6603098 Reddy Aug 2003 B2
6605185 Sasaki et al. Aug 2003 B2
6612158 Huuskonen Sep 2003 B1
6644098 Cardinale Nov 2003 B2
6647312 Sasaki et al. Nov 2003 B2
6655046 Schfer Dec 2003 B2
6655195 Grabscheid Dec 2003 B2
6675494 Oechsle Jan 2004 B1
6683297 Schulz Jan 2004 B2
6694266 Jackson Feb 2004 B1
6694870 Pietikinen Feb 2004 B1
6699362 Rautiainen Mar 2004 B1
6699365 Duan Mar 2004 B2
6707008 Roehr Mar 2004 B2
6708608 Viljanmaa Mar 2004 B2
6712935 Goodall Mar 2004 B2
6712937 Oechsle Mar 2004 B1
6712938 Leppkoski Mar 2004 B1
6715630 Littlejohn Apr 2004 B2
6716316 Grabscheid Apr 2004 B2
6728592 Wells Apr 2004 B2
6736935 Hermans May 2004 B2
6749368 Ankeny Jun 2004 B2
6749888 Linnonmaa Jun 2004 B2
6752907 Edwards Jun 2004 B2
6772533 Hassinen Aug 2004 B2
6775924 Bruntz Aug 2004 B2
6779440 Pekka et al. Aug 2004 B2
6780284 Almi Aug 2004 B2
6790536 Schnleber Sep 2004 B2
6802513 Ranzau Oct 2004 B2
6805899 MacHattie Oct 2004 B2
6807510 Backstrom Oct 2004 B1
6813941 Beuther Nov 2004 B2
6834550 Upadhyaya et al. Dec 2004 B2
6835283 Weigant Dec 2004 B2
6849851 Komulainen Feb 2005 B2
6860030 Graf Mar 2005 B1
6860033 Latti Mar 2005 B2
6863919 Maenpaa Mar 2005 B1
6866360 de Pena Mar 2005 B2
6868623 Bjornberg Mar 2005 B2
6869031 Duan Mar 2005 B2
6890407 Koivukunnas May 2005 B1
6901334 Linsen May 2005 B2
6901352 Woods May 2005 B2
6903557 Holmes Jun 2005 B2
6929716 Munch et al. Aug 2005 B2
6936794 Zhang Aug 2005 B2
6941875 Norton et al. Sep 2005 B2
6953516 Hermans Oct 2005 B2
6958691 Anderson et al. Oct 2005 B1
6962296 Hamel Nov 2005 B2
6964117 Parent Nov 2005 B2
6965099 Habeger, Jr. Nov 2005 B1
6971187 Pikal Dec 2005 B1
6975472 Stover Dec 2005 B2
6981499 Anderson et al. Jan 2006 B2
6998021 Mantyla Feb 2006 B2
7004177 Demmer Feb 2006 B2
7017279 Almi Mar 2006 B2
7042234 Buss May 2006 B2
7047153 Woods et al. May 2006 B2
7059066 Maurer Jun 2006 B2
7067039 Almi Jun 2006 B2
7068051 Anderson et al. Jun 2006 B2
7114689 Anderson, II Oct 2006 B2
7129713 Katz Oct 2006 B2
7134998 Endo et al. Nov 2006 B2
7141141 Koskinen Nov 2006 B1
7146238 Burma Dec 2006 B2
7149650 Grabscheid Dec 2006 B2
7160418 Edwards Jan 2007 B2
7164145 Shakespeare Jan 2007 B2
7168597 Jones Jan 2007 B1
7169720 Etchells et al. Jan 2007 B2
7175853 Bracht Feb 2007 B1
7191777 Brand Mar 2007 B2
7193032 Culbert Mar 2007 B2
7219024 Gamache May 2007 B2
7225558 Hagen Jun 2007 B2
7226630 Loh Jun 2007 B2
7239451 Suzuki Jul 2007 B2
7241805 Oberegger Jul 2007 B2
7246466 Turner Jul 2007 B2
7249424 Lipponen Jul 2007 B2
7263808 Massey Sep 2007 B2
7278186 Irick et al. Oct 2007 B2
7286956 Floyd et al. Oct 2007 B2
7291856 Haran Nov 2007 B2
7294838 Rae Nov 2007 B2
7303777 Baas et al. Dec 2007 B2
7321425 Haran Jan 2008 B2
7322355 Jones Jan 2008 B2
7322484 Batten Jan 2008 B2
7324904 Floyd et al. Jan 2008 B2
7363112 Cartwright Apr 2008 B2
7367164 Burton et al. May 2008 B2
7383721 Parsons et al. Jun 2008 B2
7383837 Robertson et al. Jun 2008 B2
7384509 Heikkinen Jun 2008 B2
7384516 Fitzpatrick et al. Jun 2008 B2
7404262 Jurkovich et al. Jul 2008 B2
7407562 Heikkinen et al. Aug 2008 B2
7413380 Corwon Aug 2008 B2
7429311 Pietikainen Sep 2008 B2
7441344 Savarese Oct 2008 B1
7445377 Lee Nov 2008 B2
7445830 Van Dijk Nov 2008 B2
7452447 Duan et al. Nov 2008 B2
7454253 Fan Nov 2008 B2
7459061 Passiniemi Dec 2008 B2
7459062 Mayer Dec 2008 B2
7467629 Rand Dec 2008 B2
7494567 Haran Feb 2009 B2
7496413 Fan Feb 2009 B2
7513975 Burma Apr 2009 B2
7514030 Nilsson et al. Apr 2009 B2
7524547 Beach Apr 2009 B2
7558673 Qu Jul 2009 B1
7571061 Cai Aug 2009 B2
7575659 Billings Aug 2009 B2
7584652 Floyd Sep 2009 B2
7592608 Shakespeare et al. Sep 2009 B2
7608169 Backstrom et al. Oct 2009 B2
7609366 MacHattie et al. Oct 2009 B2
7617717 Luchinger Nov 2009 B2
7627959 Reinhardt et al. Dec 2009 B2
7630847 Jones, III et al. Dec 2009 B2
7634860 Hamel Dec 2009 B2
7651775 Suzuki et al. Jan 2010 B2
7658873 Chen Feb 2010 B2
7662257 Edwards Feb 2010 B2
7695746 Bows Apr 2010 B2
7704351 Lipponen Apr 2010 B2
7718943 Johnson et al. May 2010 B2
7755368 Herrmann Jul 2010 B2
7759947 Kaufmann Jul 2010 B2
7767940 Gerth Aug 2010 B2
7777496 Evans Aug 2010 B2
7780817 Hellstrom Aug 2010 B2
7799170 Shakespeare et al. Sep 2010 B2
7811417 MacHattie Oct 2010 B2
7812947 Shakespeare Oct 2010 B2
7818934 Hall Oct 2010 B2
7819790 Grischenko et al. Oct 2010 B2
7820012 Stewart Oct 2010 B2
7827751 Plante Nov 2010 B2
7832169 Engstrom Nov 2010 B2
7851712 Luchinger Dec 2010 B2
7857777 Larson et al. Dec 2010 B2
7861673 Huisinga et al. Jan 2011 B2
7871494 Viaser Jan 2011 B2
7880156 Shakespeare Feb 2011 B2
7887867 Abboud Feb 2011 B2
7891114 Lasonde Feb 2011 B2
7892584 Castillo et al. Feb 2011 B2
7911212 Herrmann Mar 2011 B2
7923670 Hirano Apr 2011 B2
7931928 Emerson Apr 2011 B2
7938935 MacHattie May 2011 B2
7944220 Lock May 2011 B2
7946557 Chirico May 2011 B2
7955471 Kesselmayer Jun 2011 B2
7956624 Beaulieu Jun 2011 B2
7962250 Bretzner Jun 2011 B2
7964064 Weinstein Jun 2011 B2
7989732 Karogal Aug 2011 B2
8028988 Shakespeare Oct 2011 B2
8029648 Spindler Oct 2011 B2
8039031 Baianu Oct 2011 B2
8043642 Schonemann Oct 2011 B2
8092650 Munch et al. Jan 2012 B2
8155932 Berggren et al. Apr 2012 B2
8187424 Haran et al. May 2012 B2
8209048 Zehnpfund et al. Jun 2012 B2
8225810 Blanchard Jul 2012 B2
8245383 Mann et al. Aug 2012 B2
8248610 Kokko et al. Aug 2012 B2
8261465 Mayer et al. Sep 2012 B2
8277609 Hermans et al. Oct 2012 B2
8282781 Shakespeare et al. Oct 2012 B2
8294230 Yamagata et al. Oct 2012 B2
8308561 Mattice et al. Nov 2012 B2
8343290 Hueneke et al. Jan 2013 B2
8343564 Kerr et al. Jan 2013 B2
8372771 Benham et al. Feb 2013 B2
8403596 Schafer et al. Mar 2013 B2
8415595 Chirico et al. Apr 2013 B2
8449680 Burke et al. May 2013 B2
8489221 Nuyan et al. Jul 2013 B2
8506662 Makinen Aug 2013 B2
8507462 Qi et al. Aug 2013 B2
8511766 Sonnenfroh et al. Aug 2013 B2
8517963 Larson et al. Aug 2013 B2
8529660 Diekmeyer et al. Sep 2013 B2
8571715 Runkana et al. Oct 2013 B2
8608095 Naundorf et al. Dec 2013 B2
20010035273 Kuhasalo et al. Nov 2001 A1
20010037582 Ringer et al. Nov 2001 A1
20010054239 Ringer et al. Dec 2001 A1
20020088137 Savarese Jul 2002 A1
20020141945 Billingsley et al. Oct 2002 A1
20020189612 Rand Dec 2002 A1
20030000935 Roehr et al. Jan 2003 A1
20030015325 Vienot Jan 2003 A1
20030016029 Lowery et al. Jan 2003 A1
20030021819 Head et al. Jan 2003 A1
20030033727 Ensign et al. Feb 2003 A1
20030074852 Knabenschuh Apr 2003 A1
20030121323 Beuther et al. Jul 2003 A1
20030172700 Ciaccio et al. Sep 2003 A1
20040025871 Davies Feb 2004 A1
20040050385 Bonney et al. Mar 2004 A1
20040050517 Juppi et al. Mar 2004 A1
20040060676 Gron et al. Apr 2004 A1
20040079039 Shaw Apr 2004 A1
20040086606 Foster et al. May 2004 A1
20040231667 Horton et al. Nov 2004 A1
20050003083 Lipponen et al. Jan 2005 A1
20050011624 Korhonen et al. Jan 2005 A1
20050022806 Beaumont et al. Feb 2005 A1
20050098284 Heikkinen et al. May 2005 A1
20050098290 Komposch et al. May 2005 A1
20050197657 Goth et al. Sep 2005 A1
20050199842 Parsons et al. Sep 2005 A1
20050202268 Kotter et al. Sep 2005 A1
20050251289 Bonney et al. Nov 2005 A1
20050251976 Lipponen et al. Nov 2005 A1
20060062889 Houston et al. Mar 2006 A1
20060183391 Crook et al. Aug 2006 A1
20060185809 Elfrink et al. Aug 2006 A1
20060194490 Hodson et al. Aug 2006 A1
20060194902 Nie et al. Aug 2006 A1
20060240150 Delaney et al. Oct 2006 A1
20060266229 Ribich Nov 2006 A1
20060276317 Pietikainen et al. Dec 2006 A1
20070044402 Hess Mar 2007 A1
20070044416 Van Dijk Mar 2007 A1
20070142882 Quincy et al. Jun 2007 A1
20070191694 Sherman et al. Aug 2007 A1
20070209228 Meerpohl et al. Sep 2007 A1
20070224418 Van Dijk et al. Sep 2007 A1
20070240376 Engstrom Oct 2007 A1
20080029234 Latti et al. Feb 2008 A1
20080057152 Miller et al. Mar 2008 A1
20080124428 Reeve et al. May 2008 A1
20080124508 Sato May 2008 A1
20080236776 Begemann Oct 2008 A1
20080245359 Williamson Oct 2008 A1
20080248294 Cohen et al. Oct 2008 A1
20080262116 Simpson et al. Oct 2008 A1
20080311279 Kortum et al. Dec 2008 A1
20080314538 Kabus Dec 2008 A1
20090017178 Desai et al. Jan 2009 A1
20090046759 Lee et al. Feb 2009 A1
20090126219 Mathis, Jr. et al. May 2009 A1
20090133282 Rasanen et al. May 2009 A1
20090203277 Crook et al. Aug 2009 A1
20090229777 Tran et al. Sep 2009 A1
20090255922 Chirico et al. Oct 2009 A1
20090258771 Chirico et al. Oct 2009 A1
20090280909 McEniry Nov 2009 A1
20090324586 Tchessalov et al. Dec 2009 A1
20100024806 Burke et al. Feb 2010 A1
20100043326 Koester Feb 2010 A1
20100163549 Gagas et al. Jul 2010 A1
20100175341 Gilbert et al. Jul 2010 A1
20100198364 Chen et al. Aug 2010 A1
20100200570 Chirico et al. Aug 2010 A1
20100266734 Bows et al. Oct 2010 A1
20110027606 Lenhardt Feb 2011 A1
20110076511 Paolilli et al. Mar 2011 A1
20110138753 Justice et al. Jun 2011 A1
20110158555 Chang et al. Jun 2011 A1
20110160919 Orr et al. Jun 2011 A1
20110162228 Park et al. Jul 2011 A1
20110190688 Tagliaferri et al. Aug 2011 A1
20110238226 Schmidt et al. Sep 2011 A1
20110244186 Dou et al. Oct 2011 A1
20110262384 Lalor et al. Oct 2011 A1
20130078364 Von Drasek et al. Mar 2013 A9
Non-Patent Literature Citations (1)
Entry
PCT International Search Report dated Jul. 2, 2013, 12 pages.
Related Publications (1)
Number Date Country
20170037213 A1 Feb 2017 US
Provisional Applications (1)
Number Date Country
61618342 Mar 2012 US
Continuations (1)
Number Date Country
Parent 13849873 Mar 2013 US
Child 15298909 US